Missense mutation in the LDLR gene: A wide spectrum in the severity of
familial hypercholesterolemia. Mutations in Human Genetic Disease: Intech; 2012.
Familial hypercholesterolemia is usually underdiagnosed and untreated in the general population.
(4.) Civeira F, International Panel on Management of
Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous
familial hypercholesterolemia.
As can be seen in Table 2, lower levels of native thiol and higher levels of disulfide were independent of BMI, age, and gender in the logistic regression of patients with
familial hypercholesterolemia. There was a statistically significant difference between the patient and control groups in terms of the median values of the parameters.
Jacobsen, "Acquired supravalvular aortic stenosis in
familial hypercholesterolemia. A hemodynamic and angiocardiographic study," The American Journal of Medicine, vol.
Familial Hypercholesterolemia (FH) occurs in an autosomal dominant manner and is characterized by substantially elevated levels of low density lipoprotein cholesterol (LDL-C).
The report provides comprehensive information on the therapeutics under development for Heterozygous
familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
[9] It was approved by the US-FDA in July 2015 as a first-in-class drug, "for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous
familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol." The approval followed evaluation of the drug in five phase 3, double-blind, placebo-controlled trials that involved 2476 participants who received alirocumab.
Kynamro is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous
familial hypercholesterolemia.
[USPRwire, Tue Feb 02 2016] GlobalData's clinical trial report, "" provides an overview of Heterozygous
familial hypercholesterolemia (heFH) clinical trials scenario.
* Summarize current US clinical guidelines for the management of
familial hypercholesterolemia in youth (children and adolescents) and contrast them with guidelines for adults.